Deep Tech Startups

Binaural DSP works on digital signal processing for audio, including a nonlinear psychoacoustic time-invariant DAC effect. It focuses on headphone and binaural audio research.

1 investor

Bioarchitech develops oncolytic virus therapies and RNA-based immunotherapy candidates for cancer treatment. The company combines expertise in viral engineering, immunology, and preclinical development to advance novel therapeutic platforms.

1 investor

BioAscent provides integrated drug discovery services including medicinal chemistry, biosciences, computational discovery, and compound management. The company serves pharmaceutical and biotech clients requiring external research capabilities.

1 investor

Biocartesian provides optical pooled screening services for functional genomics research. The company uses its proprietary ARADIA technology to link microscopy-based cellular phenotypes with genetic perturbations, enabling researchers to conduct large-scale CRISPR screens and other genomic studies with visual, spatial, and live-cell readouts.

1 investor

BioCell Analytica provides effect-based analysis using cultured cells to detect health- and environment-hazardous contaminants in water, soil, and sediment, capturing the combined "cocktail effect" of multiple substances. It serves the water industry for testing drinking water, wastewater treatment efficiency, and chemical pollution monitoring.

1 investor

Biocellis develops a patented bioluminescence immunoassay platform that delivers laboratory-grade, picogram-level sensitivity with results in under 60 seconds in a compact, portable format for point-of-care and high-throughput screening. Its diagnostics target human health, veterinary, environmental, food safety, and public screening applications across hospitals, clinics, and field settings.</parameter> <parameter name="founders">[{"full_name": "Vincent Poher", "title": "Co-founder", "linkedin_url": "https://www.linkedin.com/in/vincentpoher/"}, {"full_name": "Thierry Rose", "title": "Co-founder", "linkedin_url": "https://www.linkedin.com/in/thierry-rose-122013254/"}, {"full_name": "Sophie Goyard", "title": "Co-founder", "linkedin_url": "https://www.linkedin.com/in/sophie-goyard-968844103/"}]</parameter> <parameter name="hq_city">Grenoble

1 investor

BioCircuit Technologies develops advanced medical devices for tissue repair and neuromodulation, with specialization in biomaterials, nitinol design, and bioelectronics. The company serves surgical teams with products like Nerve Tape®, a sutureless device for nerve repair.

1 investor

BioClé is a biotechnology company developing a delivery platform based on bacterial extracellular vesicles (bEVs) to improve the stability, bioavailability, and cellular uptake of bioactive compounds.

1 investor

BioCompute is developing DNA-based data storage technology, offering exclusive pilot programs for early access. The company operates in the data storage and biotechnology space.

1 investor

Biocrates develops standardized metabolomics kit technology and software for quantitative metabolic profiling, used to study biosamples across many biological questions. It serves scientists and researchers in pharma, academia, and health institutions, along with core facilities and CROs.

1 investor

Biocytogen (HKEX: 02315) is a global biotechnology company that uses genetically engineered mouse models and its RenMice/RenMab/RenNano fully human antibody platforms to develop therapeutic antibody drugs. It provides antibody discovery, humanized mouse models (e.g. B-NDG, immune checkpoint humanized mice), and preclinical pharmacology and CRO services to biopharma clients worldwide.

1 investor

Bio Design Lab uses synthetic biology to engineer viral vector components, offering retroviral and lentiviral vectors designed to shift transgene integration away from proto-oncogenes for improved safety and enhanced transduction efficiency. Its vectors support gene therapies, cell therapies (including T and NK cells), vaccine platforms, and protein-producing cell lines.

1 investor

Biodimension develops tissue engineering and non-animal testing methods including in-vitro platforms, biofabricated tissues, and computational models for pharmaceutical, personal care, and agrochemical industries. The company provides alternatives to animal testing for preclinical research and regenerative medicine applications.

1 investor

Bioelectrix develops a novel electrical stimulation technology to accelerate wound healing by delivering stable, controlled electrical signals to tissue. The company targets diabetic foot ulcers and other chronic wounds, with initial focus on patients for whom small wounds can become life-threatening complications.

1 investor

Bioelectronica develops hardware and software tools for accelerated antibody discovery using single-cell protein secretion sorting combined with AI-driven sequence analysis. The company serves research institutions and biotech firms in the life sciences industry.

1 investor

Bioemtech provides in vitro cell-based assays and laboratory services for drug discovery and stem cell therapy applications, utilizing cell lines and standardized protocols to measure cytotoxicity, biological activity, and biochemical mechanisms for pharmaceutical research.

1 investor

Biogenera develops BGA002, an anti-tumor therapeutic candidate targeting neuroblastoma and rhabdomyosarcoma, which primarily affect children and adolescents. The company is advancing the drug through clinical development with a structured regulatory pathway in Europe.

1 investor

Biogenes Technologies designs, develops, and commercializes animal-free aptamers for use in life science and diagnostics applications.

1 investor

Biognosys provides proteomics contract research services and software for pharma and biotech companies to support R&D, clinical trials, and clinical decision making. It develops mass-spectrometry-based proteomics tools used across drug discovery and clinical development.

1 investor

Imviva is a clinical-stage biotechnology company developing allogeneic CAR-T cell therapies for oncology and autoimmune diseases. The company focuses on creating safer, more effective off-the-shelf cell therapies designed to improve patient access and outcomes in regenerative medicine.

1 investor

Biokorf works on 3D Integrated Pharmaceuticals, including particle engineering and cocrystals for drug development.

1 investor

BioLamina develops full-length human recombinant laminin proteins and related cell culture substrates for research and clinical applications. The company's products support the growth and differentiation of pluripotent stem cells, tissue-specific cells, and organoid development in both 2D and 3D culture environments.

1 investor

Biolinco provides a platform for cell line development that uses DNA barcoding and multi-omic characterization to help biopharmaceutical companies evaluate and select optimal cell clones. The platform addresses limitations in traditional workflows that evaluate only a small number of clones.

1 investor

BioLink is a biotechnology company that develops and manufactures process equipment and consumables for life science applications, including recombinant protein drugs, vaccines, antibody drugs, cell therapy, and gene therapy production. The company supplies upstream cell culture, disposable storage and downstream chromatography, filtration, and hydration products along with process development services.

1 investor